Literature DB >> 26388103

Cannabis use and mental health-related quality of life among individuals with depressive disorders.

Itay Aspis1, Daniel Feingold2, Mark Weiser3, Jurgen Rehm4, Gal Shoval5, Shaul Lev-Ran6.   

Abstract

Cannabis is the most widely used illicit substance among individuals with depressive disorders. This study aimed to evaluate whether among individuals with depressive disorders, higher frequency of cannabis use would be associated with poorer Quality of Life (QoL), based on a large nationally representative US sample. Individuals with depressive disorders (N=3416) were divided into categories according to no use (N=3096), occasional use (less than weekly, N=176) and regular (at least weekly, N=144) use of cannabis in the past 12 months. QoL was assessed using the Short-Form 12 (SF-12) questionnaire. Women who used cannabis regularly had a significantly lower SF-12 Mental Component Summary score (MCS) compared to non-users, with a mean difference of 0.4 Standard Deviations (SDs). Comparison of subscale scores showed no significant differences. No significant difference was noted when comparing women who used cannabis occasionally to non-users. No differences were found among men when comparing MCS and mental subscale scores of both regular and occasional users to non-users. Our findings highlight the importance of taking gender and the frequency of cannabis use into account, when assessing functional and emotional aspects of cannabis use among individuals with depressive disorders.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cannabis; Depressive disorders; Dysthymia; Major depressive disorder; Quality of Life

Mesh:

Year:  2015        PMID: 26388103     DOI: 10.1016/j.psychres.2015.09.014

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  Sex Differences in the Association Between Cannabis Use and Suicidal Ideation and Attempts, Depression, and Psychological Distress Among Canadians.

Authors:  Jillian E Halladay; Michael H Boyle; Catharine Munn; Susan M Jack; Katholiki Georgiades
Journal:  Can J Psychiatry       Date:  2018-09-27       Impact factor: 4.356

2.  Marijuana and acute health care contacts in Colorado.

Authors:  George Sam Wang; Katelyn Hall; Daniel Vigil; Shireen Banerji; Andrew Monte; Mike VanDyke
Journal:  Prev Med       Date:  2017-03-30       Impact factor: 4.018

3.  Cannabis and Depression.

Authors:  Daniel Feingold; Aviv Weinstein
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Relationships between marijuana use, severity of marijuana-related problems, and health-related quality of life.

Authors:  Jung-Yu Liao; Larissa J Mooney; Yuhui Zhu; Jonathan Valdez; Caroline Yoo; Yih-Ing Hser
Journal:  Psychiatry Res       Date:  2019-03-13       Impact factor: 3.222

5.  An Event-Related Potential Study on the Effects of Cannabis on Emotion Processing.

Authors:  Lucy J Troup; Stephanie Bastidas; Maia T Nguyen; Jeremy A Andrzejewski; Matthew Bowers; Jason S Nomi
Journal:  PLoS One       Date:  2016-02-29       Impact factor: 3.240

6.  Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences.

Authors:  Laura Zielinski; Meha Bhatt; Nitika Sanger; Carolyn Plater; Andrew Worster; Michael Varenbut; Jeff Daiter; Guillaume Pare; David C Marsh; Dipika Desai; James MacKillop; Meir Steiner; Stephanie McDermid Vaz; Lehana Thabane; Zainab Samaan
Journal:  Biol Sex Differ       Date:  2017-03-30       Impact factor: 5.027

7.  Young Adults With Higher Motives and Expectancies of Regular Cannabis Use Show Poorer Psychosocial Functioning.

Authors:  Danielle Amiet; George J Youssef; Lauryn J Hagg; Valentina Lorenzetti; Linden Parkes; Nadia Solowij; Murat Yücel
Journal:  Front Psychiatry       Date:  2020-12-15       Impact factor: 4.157

8.  Attenuated reward activations associated with cannabis use in anxious/depressed individuals.

Authors:  Philip A Spechler; Jennifer L Stewart; Rayus Kuplicki; Martin P Paulus
Journal:  Transl Psychiatry       Date:  2020-06-15       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.